Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Tesaro Inc (TSRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 7,903,807
  • Shares Outstanding, K 53,870
  • Annual Sales, $ 44,820 K
  • Annual Income, $ -387,470 K
  • 36-Month Beta 1.60
  • Price/Sales 179.98
  • Price/Cash Flow 0.00
  • Price/Book 15.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
125.05 +17.33%
on 06/09/17
168.92 -13.14%
on 05/31/17
-8.45 (-5.45%)
since 05/23/17
3-Month
125.05 +17.33%
on 06/09/17
168.92 -13.14%
on 05/31/17
-6.90 (-4.49%)
since 03/23/17
52-Week
36.71 +299.67%
on 06/28/16
192.94 -23.96%
on 02/21/17
+101.55 (+224.82%)
since 06/23/16

Most Recent Stories

More News
Tesaro Inc Set to Possibly Pullback After Yesterday's Rally of 7.26%

Tesaro Inc (NYSE:TSRO) traded in a range yesterday that spanned from a low of $141.01 to a high of $152.59. Yesterday, the shares gained 7.3%, which took the trading range above the 3-day high of $146.33...

TSRO : 146.72 (-2.04%)
Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study

Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca....

AZN : 35.07 (-0.82%)
CLVS : 95.00 (-1.84%)
TSRO : 146.72 (-2.04%)
RHHBY : 32.7600 (+1.42%)
Here's Why Clovis Oncology (CLVS) Stock Skyrocketed Today

Shares of Clovis Oncology (CLVS) opened more than 40% higher on Monday morning after the company announced positive results in a late-stage trial involving its Rubraca therapy--an outcome that could help...

CLVS : 95.00 (-1.84%)
TSRO : 146.72 (-2.04%)
Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year

Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.

AZN : 35.07 (-0.82%)
CLVS : 95.00 (-1.84%)
TSRO : 146.72 (-2.04%)
RHHBY : 32.7600 (+1.42%)
TESARO Announces Participation at Goldman Sachs 38th Annual Global Healthcare Conference

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global Healthcare Conference, to be held June 13-15, 2017 at...

TSRO : 146.72 (-2.04%)
Corporate News Blog - Puma Biotech Announced Positive Results from PB272 Phase-II Data at the ASCO, 2017

Research Desk Line-up: Tesaro Post Earnings Coverage

PBYI : 87.50 (+1.21%)
TSRO : 146.72 (-2.04%)
Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain

On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).

AZN : 35.07 (-0.82%)
CLVS : 95.00 (-1.84%)
TSRO : 146.72 (-2.04%)
RHHBY : 32.7600 (+1.42%)
TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer

TESARO Inc. (NASDAQ:TSRO) and Clinigen Group plc's (AIM:CLIN) ('Clinigen') Idis Managed Access division have partnered to launch a Managed Access Program (also known as an Early Access Program) in Europe...

TSRO : 146.72 (-2.04%)
TESARO Announces Approval of VARUBY(R) (Oral Rolapitant Tablets) by European Commission

-- VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimen

TSRO : 146.72 (-2.04%)
TESARO Announces Approval of VARUBY(R) (Oral Rolapitant Tablets) by European Commission

- VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimen

TSRO : 146.72 (-2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor...

See More

Support & Resistance

2nd Resistance Point 155.79
1st Resistance Point 151.26
Last Price 146.72
1st Support Level 144.18
2nd Support Level 141.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.